GuidelineThe Korean journal of internal medicine2021
Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.
Guideline in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of Mendelian Randomization to Unveil Metabolic Markers inJournal of Korean medical science · 2026Pooled it
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.Annals of hematology · 2022Trial
- Economic Evaluation of Empirical and Tailored Helicobacter pylori Eradication Strategies Including Second-Line Therapy.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Sex-Specific Differences in Helicobacter pylori Eradication Outcomes: Treatment Success and Adverse Events in a Single Tertiary Center in South Korea.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- The Relationship between Erosive Esophagitis and Sleep Issues in Working-Aged Koreans.Gut and liver · 2026Article
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-ResistantMicroorganisms · 2025Article
- Saucerneol D Suppresses the Growth ofCurrent issues in molecular biology · 2025Article
- Clinical Effectiveness and Application Strategies of Bismuth Quadruple Therapy: Analysis of the European Helicobacter Pylori Registry (Hp-EuReg).The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Impact of Helicobacter pylori Screening on Gastric Cancer Incidence and Mortality.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Antibiotic Resistance of Helicobacter pylori: Current Trends in Daegu-Kyungpook.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Etiology and Therapeutic Strategies for Refractory Peptic Ulcers: A Comprehensive Review.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- In Vitro Susceptibility and Synergistic Effect of Bismuth AgainstAntibiotics (Basel, Switzerland) · 2024Article
- [Current Status and Future Perspectives of Tegoprazan-BasedThe Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- Types of 23S Ribosomal RNA Point Mutations AffectingThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- OptimizingGut and liver · 2023Review
- [Vonoprazan-based Dual and Triple Therapy forThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Efficacy of 7-day Tailored Therapy forThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- Development of a New Liquid Type Rapid Urease Test Kit (HelicotestThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Article
- Stomach cancer burden in China: Epidemiology and prevention.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori infection is one of the most common infectious diseases worldwide. H. pylori is responsible for substantial gastrointestinal morbidity with a high disease burden. Since the revision of the H. pylori Clinical Practice Guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin based triple therapy. According to a nationwide randomized controlled study by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance to clarithromycin. The clinical practice guidelines for treatment of H. pylori were updated based on evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines were designed to provide clinical evidence for the treatment of H. pylori to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards, and will be revised if more evidence emerges in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.